Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Burkitt Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lung Neoplasms 4Meningeal Carcinomatosis 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Glioma 2Glioblastoma 2Astrocytoma 2Uveal Melanoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Nevus 1Meningeal Neoplasms 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Monocytic, Acute 1Leukemia, Hairy Cell 1Germinoma 1Diabetes Insipidus 1

Interventions

venetoclax 91Azacitidine 75Cytarabine 68Specimen Handling 45fludarabine 44Biopsy 32Cyclophosphamide 29Daunorubicin 27fludarabine phosphate 25Injections 25Decitabine 25Idarubicin 24Busulfan 20Granulocyte Colony-Stimulating Factor 19Whole-Body Irradiation 18Mycophenolic Acid 18Tacrolimus 17Melphalan 17decitabine and cedazuridine drug combination 16gilteritinib 14Stem Cell Transplantation 14CPX-351 14Mitoxantrone 13Peripheral Blood Stem Cell Transplantation 11Magnetic Resonance Spectroscopy 11Filgrastim 11Etoposide 11Cladribine 11ivosidenib 10revumenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Spinal Puncture × 90 days × Clear all
NCT07012044 2026-05-27

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1 Recruiting
47 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06504459 2026-04-13

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

OHSU Knight Cancer Institute

Phase 2 Recruiting
40 enrolled
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT06871410 2026-03-24

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 1 Recruiting
26 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡